Aclaris Therapeutics, Inc. reported $8.2M of revenue over the trailing twelve months, −51% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $8.2M (to Q2 2026). Net income: −$76M, trailing twelve months to Q2 2026. Free cash flow: −$62M, trailing twelve months to Q2 2026. Operating margin: −1219%, trailing twelve months to Q2 2026.

ACRSAclaris Therapeutics, Inc.

Healthcare

$3.78+105% 1Y

$3.78

$1.8152 weeks$6.54

ACRS as reported

Aclaris Therapeutics, Inc. reported $8.2M of revenue over the trailing twelve months, −51% on the year before. 10 reported series are charted on this page, each one as filed.

$8.2M

Revenue, trailing twelve months · to Q2 2026 · −51% against the twelve months before

Net income: −$76M
Net income · −44% year on year · trailing twelve months to Q2 2026
Free cash flow: −$62M
Free cash flow · +519% year on year · trailing twelve months to Q2 2026
Operating margin: −1219%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ACRS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$8.2M	−51%	Q2 2026
Net income	−$76M	−44%	Q2 2026
EPS	−$0.58	−63%	Q2 2026
Gross margin	77%	n/a	Q2 2026
Operating margin	−1219%	n/a	Q2 2026
Net margin	−1071%	n/a	Q2 2026
ROE	−73%	n/a	Q2 2026
ROA	−50%	n/a	Q2 2026
ROIC	817%	n/a	Q2 2021 · 20 quarters behind
Free cash flow	−$62M	+519%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.